TXG 10x Genomics, Inc.
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1770787 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.6%
TTM net income YoY12.1%
TTM EPS YoY17.5%
Revenue 3-yr CAGR1.5%
Net income 3-yr CAGR—
Margins
Gross margin71.9%
Operating margin-11.7%
Net margin-10.8%
FCF margin15.2%
EBITDA margin-5.3%
Returns
ROE-8.3%
ROA-6.4%
ROIC (approx.)-17.2%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets21.2%
Debt / equity0.00x
Current ratio5.12x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-1.49x
Accruals ratio-16.0%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $642.82M | $610.78M |
| Cost of revenue | $198.94M | $196.30M |
| Gross profit | $443.88M | $414.48M |
| R&D expense | $238.63M | $264.70M |
| SG&A expense | $316.13M | $344.34M |
| Operating income | -$60.98M | -$194.56M |
| Interest expense | $0 | $4,000 |
| Pretax income | -$39.91M | -$177.70M |
| Income tax | $3.64M | $4.93M |
| Net income | -$43.54M | -$182.63M |
| EBITDA | -$24.79M | -$158.68M |
| EPS (basic) | -0.35 | -1.52 |
| EPS (diluted) | -0.35 | -1.52 |
| Weighted avg. shares (diluted) | 124.75M | 120.45M |
| Balance sheet | ||
| Cash & equivalents | $473.97M | $344.07M |
| Short-term investments | $49.44M | $49.34M |
| Receivables | $47.01M | $87.86M |
| Inventory | $56.34M | $83.11M |
| Current assets | $684.45M | $584.39M |
| PP&E, net | $226.71M | $252.65M |
| Goodwill | $4.51M | $4.51M |
| Intangibles | $62.33M | $15.67M |
| Total assets | $1.04B | $918.64M |
| Current liabilities | $153.45M | $117.63M |
| Total liabilities | $245.04M | $208.50M |
| Shareholders' equity | $796.33M | $710.13M |
| Shares outstanding | 127.69M | 122.29M |
| Cash flow statement | ||
| Operating cash flow | $136.05M | $6.66M |
| Capital expenditure | $5.93M | $12.39M |
| Free cash flow | $130.12M | -$5.73M |
| Investing cash flow | -$13.44M | -$32.63M |
| Financing cash flow | $6.80M | $10.91M |
| Depreciation & amortization | $36.20M | $35.88M |
| Stock-based compensation | $109.12M | $140.75M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.